Androgens such as testosterone can promote prostate cancer growth, so for years standard treatment for prostate cancer has included drugs that suppress the production of testosterone. Many prostate cancers become resistant to this treatment.
Enzalutamide is an androgen-receptor inhibitor, and previous trials have suggested that it might delay the development of resistance to hormone suppression and hence increase survival.
In a new trial of 1,125 men with metastatic, hormone-sensitive prostate cancer, those who received testosterone suppression, enzalutamide and a chemotherapeutic agent had significantly longer progression-free and overall survival compared with the current standard of care. Side effects were more common in this group.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stower, H. A new strategy for prostate cancer. Nat Med 25, 1798 (2019). https://doi.org/10.1038/s41591-019-0680-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-019-0680-3
